Company intelligence / Profile preview
Symic Biomedical
San Francisco, California, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Symic Biomedical's lead program, SB-030, is a peptide-heparin conjugate developed to inhibit platelet activation at sites of vascular injury, aiming to reduce restenosis and scarring after vascular interventions. SB-030 has advanced through Phase 2 and, following FDA guidance, has been considered for direct advancement to Phase 3 in selected indications[4].
- Therapeutic areas
- Cardiovascular
- Modalities
- PeptidesPeptide-drug conjugateSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Symic Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symic Biomedical.